Interesting to see how the ptx200’s progression-free survival data is holding up on the phase 1b Ovarian readout;
AstraZeneca and Merck & Co. have just had a set back:
https://www.biopharmadive.com/news/astrazeneca-merck-lynparza-cediranib-ovarian-cancer/574019/
"Measured by progression-free survival, or the length of time patients live without their tumors getting larger or spreading, the Lynparza-cediranib combination did no better than platinum-based chemotherapy."
Ann: Encouraging data from PTX-200 ovarian cancer trial, page-171
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.0¢ |
Change
-0.001(2.44%) |
Mkt cap ! $32.21M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 4.0¢ | 3.9¢ | $35.17K | 896.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350000 | 3.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.0¢ | 163887 | 2 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| PTX (ASX) Chart |